Ken Griffin Akari Therapeutics PLC Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.41 - $12.8 $6,332 - $197,708	15,446 New	15,446 $7,000
Q2 2022 Aug 15, 2022	SELL	$0.95 - $1.22 $21,570 - $27,701	-22,706 Reduced 60.12%	15,064 $15,000
Q3 2021 Nov 15, 2021	SELL	$1.59 - $1.87 $23,047 - $27,105	-14,495 Reduced 27.73%	37,770 $62,000
Q2 2021 Aug 16, 2021	BUY	$1.69 - $2.85 $41,494 - $69,976	24,553 Added 88.6%	52,265 $90,000
Q1 2021 May 17, 2021	BUY	$1.81 - $3.88 $50,158 - $107,522	27,712 New	27,712 $73,000
Q3 2020 Nov 16, 2020	SELL	$1.58 - $2.37 $29,952 - $44,928	-18,957 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.16 - $2.61 $21,990 - $49,477	18,957 New	18,957 $41,000

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $165M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.